Zheng, Qinheng http://orcid.org/0000-0002-8440-8673
Zhang, Ziyang http://orcid.org/0000-0003-0541-7211
Guiley, Keelan Z.
Shokat, Kevan M. http://orcid.org/0000-0001-8590-7741
Funding for this research was provided by:
Howard Hughes Medical Institute
Damon Runyon Cancer Research Foundation (DRG-2434-21, DRG-2281-17, DRG-2399-20)
Article History
Received: 21 August 2023
Accepted: 30 January 2024
First Online: 5 March 2024
Competing interests
: K.M.S., Z.Z. and Q.Z. are inventors on patents related to covalent K-Ras-G12D inhibitors reported here. K.M.S. is an inventor on patents owned by University of California San Francisco covering KRAS targeting small molecules licensed to Araxes, Erasca and Novartis. K.M.S. has consulting agreements for the following companies, which involve monetary and/or stock compensation: BioTheryX, BridGene Biosciences, eFFECTOR Therapeutics, Erasca, G Protein Therapeutics, Ikena, Initial Therapeutics, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Nested, Nextech, Novartis, Radd Pharma, Revolution Medicines, Rezo, Totus, Turning Point, Type6 Therapeutics, Vevo, Vicinitas and Wellspring Biosciences (Araxes Pharma). The remaining authors declare no competing interests.